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ORIGINAL ARTICLE
Introduction. Polycystic ovarian disease (PCOS) can account for up to 35 - 40% of the female factor causes of infertility. These patients 
present as medically complex cases and are challenging to manage and treat successfully. They are resistant to treatment and are often 
offered controlled ovarian stimulation (COS) and in vitro fertilisation (IVF) technology.
Aim. The aim of this study was to assess whether there was a difference in the pregnancy outcomes of women with PCOS when a 
standard gonadotrophin-releasing hormone (GnRH) antagonist (cetrorelix) protocol was used for ovarian stimulation, compared with 
non-PCOS patients undergoing IVF. 
Methods. A retrospective patient record audit was performed on 142 patients with PCOS and 501 non-PCOS patients undergoing a 
similar cetrorelix-based COS treatment protocol during a specified time period. 
Results. The main primary outcome was an ongoing pregnancy at 12 weeks, achieved in 34% of patients in the PCOS group and 27% in 
the non-PCOS group. This was not significantly different (p=0.07). No patient in the PCOS group experienced severe hyperstimulation 
syndrome.
Conclusion. There was no significant difference in pregnancy rates in patients with PCOS undergoing GnRH-antagonist ovarian 
stimulation compared with non-PCOS patients. The fact that no hyperstimulation syndrome occurred makes this an attractive option for 
women with PCOS.
At least 25% of couples experience some delay in achieving a 
desired or planned pregnancy, and 10% remain involuntarily 
childless before seeking medical assistance.1 Ovulatory dysfunction 
and tubal and peritoneal factors are prevalent at all ages, and male 
factors and unexplained causes are more common  in older couples.2 
Anovulation and oligo-ovulation account for approximately 40% of 
female infertility factors, and in this group polycystic ovarian disease 
(PCOS) is the predominant factor (80%).3,4 A definite diagnosis 
of PCOS can be made in 70 - 80% of anovulatory infertility.5 
Standardised diagnostic criteria for PCOS have been accepted 
following a consensus meeting in Rotterdam in 2003.6
Induction of ovulation for the purposes of infertility management 
in the typical PCOS patient with concomitant metabolic syndrome 
should be preceded by weight loss and lifestyle modification. Clark 
et al. and Norman et al. found that 90% of patients who lost 5% or 
more of body weight returned to ovulation, with 60% becoming 
pregnant within 18 months.7,8 Insulin sensitisation using drugs 
such as metformin, a biguanide, has been used as both an adjunct 
and an alternative to clomiphene citrate in patients who are not 
successful in achieving ovulation or pregnancy.9-11 A recent review 
concluded that metformin is highly effective in achieving ovulation 
in the clomiphene citrate-resistant PCOS patient, but should not be 
used as a first-line treatment modality.12 In vitro fertilisation (IVF) 
technology is an effective treatment option after repeated ovulation 
induction failure using clomiphene citrate and gonadotrophin 
therapy. The initial gonadotrophin-releasing hormone (GnRH) 
analogues used in controlled ovarian stimulation were the GnRH 
agonists. Problems caused by GnRH agonists were mid-cycle 
gonadotrophin flares, a high incidence of multiple pregnancies and 
ovarian hyperstimulation syndrome (OHSS).13
The introduction of newer GnRH analogues, the GnRH antagonists, 
created the potential for milder stimulation protocols that are 
better tolerated and less costly, have a quicker onset of action, result 
in a lower incidence of luteinising hormone (LH) surge, and are 
associated with a lower multiple pregnancy rate.14-17 Reviews and 
meta-analyses have recently compared the two GnRH analogues – 
the agonists with the antagonists – and have found no significant 
difference in fertilisation rate and pregnancy outcome.16-19 Two 
recent meta-analyses of pregnancy and neonatal outcome after 
IVF in PCOS patients versus non-PCOS patients have shown 
an increased cycle cancellation rate, more oocytes retrieved per 
retrieval, a lower fertilisation rate, and increased pregnancy and 
neonatal complications in patients with PCOS.17,19 From an assisted 
reproduction technology (ART) perspective, pregnancy and live 
birth rates per cycle were similar in the two groups.16
Patients with PCOS undergoing ART usually show an increased 
response to gonadotrophins and consequently produce large numbers 
of follicles and oocytes. Furthermore, they also tend to have higher 
serum oestradiol levels, resulting in an increased risk of OHSS.20
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Literature on the comparative effect and pregnancy outcome of the 
use of GnRH antagonists for ovulation induction in PCOS patients 
is limited.21 A Medline literature search yielded three limited studies, 
which were presented as abstracts, comparing IVF outcomes of 
patients with and without PCOS when GnRH antagonists were used 
for pituitary down-regulation.22-24 In summary, they reported that 
pregnancy outcome with GnRH antagonist use in PCOS patients 
undergoing controlled ovarian stimulation did not differ from 
pregnancy outcome in non-PCOS patients. In a very recent study,25 
a GnRH antagonist was compared with a GnRH agonist in PCOS 
patients. No differences were found in outcome in the two groups 
with regard to number of oocytes retrieved, number of embryos 
transferred, and clinical pregnancy rates. There was also no case of 
OHSS in the antagonist group. 
Study aim
We aimed to compare the stimulation characteristics and IVF 
(embryo transfer (ET)) pregnancy outcomes of women with PCOS 
using a standard GnRH antagonist (cetrorelix) protocol for ovarian 
stimulation with non-PCOS patients undergoing IVF using a 
similar protocol. Essentially the study question was whether GnRH 
antagonists work equally well in PCOS and non-PCOS patients. 
Materials and methods
Study design and patient characteristics
The study was a retrospective observational cohort clinical audit and 
patient record review of two groups of patients who entered an ART 
programme between January 2005 and December 2007 (3 years). 
The entire data set available was collected for both groups. The 
first group included all patients during this time period (N=142) 
diagnosed as having PCOS and requiring controlled ovulation 
induction using a GnRH antagonist (cetrorelix) regimen for IVF/
intracytoplasmic sperm injection (ICSI) purposes (cetrorelix-
PCOS group). Before inclusion in this study group, a documented 
diagnosis of PCOS was made according to the Rotterdam criteria,8 
and other causes of hirsutism/anovulation were excluded.
The second group (N=501) included all patients during the same 
period who did not have a diagnosis of PCOS but did require 
controlled ovulation induction using a cetrorelix regimen (cetrorelix-
non-PCOS group). Both groups were part of a controlled ovarian 
stimulation protocol for the purposes of either IVF or ICSI. The 
demographic characteristics of the two groups are set out in Table I.1
As set criteria for ICSI, the following thresholds were used for male 
factor: count less than 10 million/ml, motility less than 30%, and 
morphology less than 5.
Controlled ovulation induction
The general controlled ovulation induction protocol used in our 
patients can be outlined as follows, allowing for some slight 
individual but not significant variation. The patients were all given 
the GnRH antagonist cetrorelix (Cetrotide; Serono International, 
Geneva, Switzerland) for the purposes of LH surge inhibition. 
Cetrorelix was usually given as a fixed depot dose of 3 mg on day 
8, occasionally following a flexible protocol. Ovarian stimulation 
was achieved by administering follicle-stimulating hormone (FSH)/
human chorionic gonadotrophin (HCG) (Menopur) or FSH (Gonal 
F) alone. This was mainly done using a step-up protocol, starting 
1 
with 2 units a day on day 4 and increasing the dose after day 8 if 
needed. The patients were then followed up with serial ultrasound 
determination of follicle development. The criteria for triggering 
ovulation were based on follicle data, triggering when the leading 
follicle achieved 18 mm and at least two other follicles achieved 16 
mm or more. ET was performed between days 2 and 5, depending 
on the number of good-quality embryos. Progesterone 600 mg per 
day was given for luteal phase support after transfer. 
Outcome measurement
On days 10 - 14 after ET, a blood sample was taken to assess the βhCG 
value: if this was >10 IU/l, the test was repeated 4 days later to confirm 
pregnancy. Pregnancy was defined as a 66% rise in serum βhCG in 48 
hours. In the case of a positive pregnancy, ultrasound was performed 
at 7 weeks after ET to assess the number of fetal sacs and heart 
activity. Clinical pregnancy was defined as the presence of a fetal sac, 
with or without heart activity. As a second primary outcome, ongoing 
pregnancy was defined as positive heart activity at a gestational age of 
12 weeks. In this study we report the ongoing pregnancy rate.
Statistics
The primary outcome measures possible with the data collected 
were total number of oocytes retrieved and pregnancy rates. The 
patient population used for the analyses of the primary efficacy 
endpoints were defined as all patients with either a diagnosis of 
PCOS or not, undergoing a cetrorelix-based controlled ovarian 
stimulation procedure without major deviation from the protocol 
described above. Microsoft Excel 2002 software was used for data 
collection and statistical analysis. 
Discrete data were compared with the chi-square test or Fisher’s 
exact test where the expected value in any cell of a two-by-two table 
was less than 5. The means of normally distributed continuous 
data were compared by analysis of variance, while the medians of 
continuous data that were not distributed normally were calculated 
using the non-parametric Mann-Whitney U-test. A p-value of <0.05 
was considered to be statistically significant, where applicable.
This study was exempt from the institutional ethics and review 
committee because of its retrospective, non-intervention nature, and 
the maintenance of total confidentiality. Data were accessed as part 
of an ongoing clinical audit.
Results
Table I sets out the demographic characteristics of the two 
groups, broken up as the two main study groups (PCOS and non-
PCOS), as well as within-group assessment according to the 
assisted reproduction technique used (IVF and ICSI). There was 
no difference between the groups with regard to age. The main 
reasons for infertility in the non-PCOS group were male factor 40%, 
idiopathic 29%, endometriosis 18%, tubal factor 11% and other 2%. 
In the groups described above, the number of oocytes retrieved 
was assessed as being different or not. The result of this analysis is 
presented in Table II. Similar numbers of oocytes were retrieved in 
both IVF groups and in both ICSI groups. Furthermore, there was 
no difference in oocyte retrieval between the PCOS and the non- 
PCOS groups. Two embryos were strictly transferred in all patients 
in the PCOS group as well as in the non-PCOS group.
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The second primary outcome measure was a successful ongoing 
pregnancy. This outcome was also compared in the different study 
groups, and the results of the analysis are presented in Table III. 
There was no significant difference between the IVF ongoing 
pregnancy rate (46.3%) and the ICSI pregnancy rate (29.7%) in the 
PCOS group (p=0.979). The same was true of the non-PCOS group 
(IVF 30.95% v. ICSI 24.92) (p=0.27) (Table III).
There was also no difference between total pregnancy rates in the 
PCOS group (34.5%) and the non-PCOS group (26.95%) (p=0.19) 
(Table III).
No case of severe OHSS was reported in either the PCOS or the 
non-PCOS group.
In the PCOS group, there were 49 pregnancies. Seven of these ended 
in a miscarriage (14.3%). The miscarriage rate in the control group 
was 12.7%. This difference was not significant. The twin pregnancy 
rate in the PCOS group was 15.4% and in the non-PCOS group 14.8%.
Discussion
Infertility patients requiring controlled ovarian stimulation (COS) 
may be managed with three different options: (i) FSH with a GnRH 
antagonist; (ii) clomiphene/FSH with a GnRH antagonist; or (iii) the 
long-course GnRH agonist protocol.26 The use of a GnRH agonist to 
suppress elevated LH and androgen levels and to prevent premature 
LH surges in COS has been successful in reducing the miscarriage 
rate and improving the pregnancy rate.24 It has been proposed that 
the newer GnRH antagonists may even be better for COS in the 
difficult patient subgroup.14 Antagonists have been shown to be 
better than agonists in general and PCOS infertility patients in that 
antagonists require the use of less gonadotrophin, result in better 
patient compliance and are associated with a lower rate of OHSS.22,23 
The main purpose of this study was to assess whether PCOS patients 
had similar infertility treatment outcomes to patients with infertility 
problems other than PCOS when using a GnRH antagonist protocol 
for COS.
The data for our two main groups, PCOS and non-PCOS, were 
generally comparable. Age and endometrial thickness did not 
differ significantly (Table I). The sample size was different, but this 
simply reflected the study population, i.e. all patients undergoing 
COS treatment. Approximately 22% of the infertility patients had 
a formal clinical diagnosis of PCOS, which corresponds with the 
proportion of infertility patients with PCOS.3,4 
The total number of oocytes retrieved per cycle was not significantly 
different in the PCOS and the non-PCOS groups (Table II). This 
lack of significant difference is contrary to the finding that PCOS 
patients generally produce larger numbers of oocytes per stimulated 
cycle17,18 and may be a result of the less complex COS and IVF/ICSI 
protocols used in our unit. It was also very encouraging to note that 
Table II. Oocytes retrieved
                                    PCOS                                     Non-PCOS
IVF ICSI Total IVF ICSI Total
Oocyte quantity (mean (SD))* 7.19  (4.85) 7.46  (5.83) 7.38  (5.55) 7.26  (4.96) 7.16  (4.40) 7.19  (4.59)
*No significant difference in any category analysis (p>0.05).
Table III. Ongoing pregnancy rate
                                  PCOS                                     Non-PCOS
IVF ICSI Total IVF ICSI Total
Ongoing pregnancy 
rate
19/41 30/101 49/142 52/168 83/333 135/501
(46.3%)a (29.7%)b (34.5%)c (30.95%)d (24.92%)e (26.95%)f
(a) v. (b) p=0.1979; (d) v. (e) p=0.27; (c) v. (f)  p=0.19.
Table I. Characteristics of patients in the two study groups
                                     PCOS                                  Non-PCOS
IVF ICSI Total IVF ICSI Total
Group size (N) 41 101 142 168 333 501
Age (yrs) (mean (SD), 34.24  (3.74) 33.89  (4.20) 33.99  (4.06 )* 34.48  (4.43) 34.86  (4.58) 34.73  (4.53)*
  range) 28 - 43 26 - 44 26 - 44 21 - 43 20 - 44 20 - 44
Endometrial thickness‡ (mm) (mean (SD))26.75  (36.56) 24.98  (35.11) 25.49  (35.41)† 17.78  (27.15) 18.03  (27.56) 20.24  (30.23)†
*No significant difference (p>0.05).
†Significantly different (p=0.079465).
‡Endometrial thickness at embryo transfer.
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there was no case of severe hyperstimulation in either of the two 
groups.
The primary endpoint of this study was a successful ongoing 
pregnancy. Table III summarises the success rates in the two main 
groups. Each of these groups, i.e. PCOS and non-PCOS, was 
further divided into patients having IVF or ICSI after COS. The 
overall pregnancy success rate was higher for the PCOS group 
(34%) than the non-PCOS group (27%), although this difference 
was not statistically significant (p=0.0785). Certainly the PCOS 
patient does not suffer a decline in pregnancy outcome when the 
antagonist-based protocol is used. These overall pregnancy rates 
achieved in our treatment protocols are similar to those achieved 
in published fertility programmes – approximately 35%.27 It is also 
interesting to note that IVF has better results than ICSI in terms of 
pregnancy outcome. This may be explained by the fact that other 
pathology may be involved with the infertility diagnosis, especially 
when resorting to ICSI in an assisted reproduction programme. The 
miscarriage rates in the PCOS (14.3%) and the non-PCOS (12.7%) 
groups were not significantly different. 
With the limits of a retrospective study, our analysis still enables us 
to conclude that there were no significant differences in procedural 
and pregnancy success in patients with PCOS undergoing GnRH-
antagonist ovarian stimulation compared with non-PCOS 
patients in whom the same controlled ovarian stimulation was 
used. Of importance is the fact that there was no case of severe 
hyperstimulation syndrome in the PCOS group, making the use of 
the GnRH antagonist an attractive option in this high-risk group of 
patients. In the South African setting the use of cetrorelix for PCOS 
patients is definitely a safe option. 
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